| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 5 | |
| #2 | Australia | 2 | |
| #3 | Canada | 2 | |
| #4 | Japan | 2 | |
| #5 | United States | 2 | |
| #6 | WIPO (World Intellectual Property Organization) | 2 | |
| #7 | Brazil | 1 | |
| #8 | EAPO (Eurasian Patent Organization) | 1 | |
| #9 | Hungary | 1 | |
| #10 | Mexico | 1 | |
| #11 | Norway | 1 | |
| #12 | New Zealand | 1 | |
| #13 | Poland | 1 | |
| #14 | Singapore | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Medical preparations | |
| #3 | Microorganisms |
| # | Name | Total Patents |
|---|---|---|
| #1 | Fakhrai Habib | 22 |
| #2 | Shawler Daniel L | 13 |
| #3 | Fakhrai Farideh | 3 |
| #4 | Habib Fakhrai | 1 |
| #5 | Daniel L Shawler | 1 |
| Publication | Filing date | Title |
|---|---|---|
| PL388997A1 | General purpose vaccine made of neoplastic cells for therapeutical and prophylactic anticancer use | |
| CA2673607A1 | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization | |
| EP2087115A2 | Blocking of gene expression in eukaryotic cells | |
| US7101543B2 | Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells | |
| EP2314322A1 | Compositions containing genetically modified lung cancer cells expressing a TGF-beta inhibitor |